相关实验视频
Updated: Jan 14, 2026

07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
20.0K
通过调节SOCS2 / JAK2 / STAT3信号通路,RP105在败血症中发挥肝脏保护作用
Qin Deng1, Hong Duo2, Qifa Ye2
1Department of Transplantation, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
International journal of molecular medicine
|October 17, 2025
概括
辐射保护剂105 (RP105) 通过与细胞因子信号传递抑制剂2 (SOCS2) 相互作用,减轻败血症引起的肝损伤. 这种相互作用抑制了JAK2 / STAT3通路,减少炎症和亡,提供了潜在的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
背景情况:
- 败血症引起的肝损伤是死亡的主要原因,由炎症失调驱动.
- 已知辐射保护剂105 (RP105) 能调节炎症,但其在败血性肝损伤中的具体作用尚不清楚.
研究的目的:
- 为了研究RP105对败血症驱动的肝损伤的保护机制.
- 阐明RP105与性肝损伤中关键信号通路之间的相互作用.
主要方法:
- 在RP105淘汰赛 (KO) 和野生型 (WT) 小鼠中,通过结和穿孔 (CLP) 诱导了败血症.
- 通过生物化学标记 (ALT/AST),组织学,炎症和亡标记来评估肝损伤.
- 用RNA测序,共免疫沉降 (Co-IP) 和西部涂抹来识别分子相互作用和通路激活.
主要成果:
- 与CLP后的WT小鼠相比,RP105-KO小鼠显示出明显恶化的肝损伤,炎症增加和亡.
- RNA测序确定了抑制细胞因子信号传递2 (SOCS2) 作为一个关键的RP105-调节基因.
- RP105直接与SOCS2结合,抑制JAK2/STAT3信号通路,该通路在RP105-KO小鼠中过度激活.
结论:
- 通过结合SOCS2,RP105可以防止败血性肝损伤,从而抑制JAK2/STAT3信号传递,减少炎症和亡.
- RP105-SOCS2相互作用代表了减轻败血症引起的肝损伤的新机制.
- RP105/SOCS2轴为治疗败血症引起的肝损伤提供了潜在的治疗点.
相关概念视频
The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K

